Compare SIF & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIF | CLDI |
|---|---|---|
| Founded | 1913 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.1M | 2.4M |
| IPO Year | 1995 | 2021 |
| Metric | SIF | CLDI |
|---|---|---|
| Price | $21.40 | $1.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 110.0K | 64.2K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.67 | N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | ★ $111,212,000.00 | $45,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.75 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.88 | $0.09 |
| 52 Week High | $29.00 | $1.93 |
| Indicator | SIF | CLDI |
|---|---|---|
| Relative Strength Index (RSI) | 43.73 | 54.67 |
| Support Level | $20.12 | $0.15 |
| Resistance Level | $23.22 | $1.42 |
| Average True Range (ATR) | 1.11 | 0.09 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 22.19 | 35.26 |
SIFCO Industries Inc produces forgings, sub-assemblies, and machined components for the Aerospace and Energy markets. Its services include forging, heat treating, machining, surface treatment, non-destructive testing, and sub-assembly of forged components. The company manufactures envelopes and precision forgings, as well as rough and finished machined parts, serving OEMs, Tier 1 and Tier 2 suppliers, and aftermarket providers across Aerospace, Defense, Energy, and Commercial Space. Its Products are made from steel, high-temperature alloys, nickel alloys, titanium, and aluminum, and include components for aircraft and industrial gas turbine engines, airframe structures, landing gear, wheels and brakes, helicopter rotating parts, and other commercial and industrial applications.
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.